Digital Therapeutics

By Mallory Hackett 11:56 am September 21, 2020
Teva Respiratory, an affiliate of Teva Pharmaceutical Industries, completed its digital inhaler portfolio today with the launch of two new products: the AirDuo Digihaler and the ArmonAir Digihaler. Both of the new inhalers are prescription inhalation powders designed to treat people with asthma 12 years and older. The AirDuo can be used to control symptoms of asthma and to prevent symptoms such...
By Mallory Hackett 01:01 pm September 18, 2020
Digital healths’ moment in the sun doesn’t appear to be ending anytime soon, and one area that is just beginning its journey into virtual care is the pharmaceutical industry.  In recent years, pharma has taken an interest in the digital health space, and even before the pandemic hit, experts from HealthXL expected 2020 to be a big year for digital therapeutics in pharma.  This morning at the DTx...
By Dave Muoio 03:35 pm September 17, 2020
The increased adoption of virtual care technologies during the COVID-19 public health emergency is fairly well documented by this point, but a widespread embrace of health technologies is providing a similar upswell on individual niches within the digital health landscape. One such group of beneficiaries are the companies working to develop, validate and distribute digital therapeutics. Speaking...
By Dean Koh 12:03 am September 16, 2020
Taiwan-based digital health startup Health2Sync has entered into a partnership with pharma giant Sanofi with the aim to apply the digital solution provided by Health2Sync in 300 clinics and hospitals nationwide certified by Taiwan Diabetes Shared Care Network over the next three years. As part of the partnership, Health2Sync will provide patient management software for healthcare professionals...
By Dave Muoio 04:53 pm September 11, 2020
International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia. The treatment, referred to as CT-155, will be a mobile app built on Click's proprietary tech platform, the companies said. Employing cognitive and neurobehavioral...
By Jonah Comstock 10:54 am September 10, 2020
While some of the more obvious barriers to digital therapeutics adoption in Europe have come crashing down recently, adoption is still hampered by cultural momentum. That was the conclusion of a group of digital therapeutics stakeholders who presented at HIMSS & Health 2.0 Europe Digital Event today, in a session moderated by YourCoach Health chairman and COO Eugene Borukhovich. “Once a...
By Dave Muoio 01:40 pm August 31, 2020
Pear Therapeutics highlighted data today from two studies of a digital cognitive behavioral therapy that acted as the precursor for Somryst, the prescription digital therapeutic for adults with chronic insomnia that was the first to pass through the FDA's Pre-Cert pilot pathway. The first, a randomized controlled trial of 1,149 Australian adults with insomnia and depressive symptoms, suggested...
By Mallory Hackett 10:52 am August 20, 2020
The use of cognitive-behavioral therapy interventions, such as Big Health’s Sleepio program, has been found to improve both sleep and mental health in individuals with insomnia and clinically significant depressive symptoms, according to new research published in the Journal of Sleep Research.   Sleepio is a digital sleep-improvement program that offers personalized treatment base on a user’s...

Credit: NuvoAir

By Sara Mageit 04:41 am August 18, 2020
Sweden-based digital therapeutics respiratory company, NuvoAir, has been certified as a Class Im medical device. The NuvoAir Home platform includes Air Next, a certified bluetooth spirometer, a connected patient app and a healthcare portal.   WHY IT MATTERS Patients can use the platform to self-monitor their respiratory health and share clinically relevant data with their care teams, who can view...
By Dave Muoio 12:14 pm July 29, 2020
A retrospective analysis of more than 2,000 Livongo Diabetes Prevention Program (DPP) participants found an average weight loss of 5.1% from baseline after 12 months, and 6.6% among those who designated as high engagers. The study, conducted by Livongo and published in BMJ Open Diabetes Research & Care, honed in on the relationships between specific program behaviors and program engagement...